Clinical trials: Vascular Conditions
Intracerebral Hemorrhage, Cerebral Hemorrhage
High Risk of Death or Disability in Brain Hemorrhage: Role of Spot Sign and Secondary Markers
This study looks at patients with brain hemorrhage to see if a special sign on brain scans, called the "Spot Sign," combined with other scan features, can predict a higher risk of death or disability.
- Conditions
- Intracerebral Hemorrhage, Cerebral Hemorrhage, Stroke, Brain Injuries
- Trial name
- NCT07172542
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier de Gonesse
Acute Myocardial Infarction (AMI)
Using Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack
Acute myocardial infarction with ST-segment elevation (STEMI) remains a leading cause of morbidity and mortality worldwide. Although advances in reperfusion therapy have reduced early mortality, many patients later develop…
- Trial name
- NCT07268391
- Testing
- Blood analysis, spectral CT scan and cardiac magnetic resonance imaging (CMR) study, Blood analysis and spectral CT study
- Where
- 4 sites in Spain
- Volunteers
- 95 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Cardiovascular Complication, Pulmonary Embolism
MACE and PE in Elective Primary TKA & THA
This study ought to identify the occurence of the major adverse cardiovascular events (MACE) and the pumonary emoblism (PE) in patients undergoing elective primary THA \& TKA
- Conditions
- Cardiovascular Complication, Pulmonary Embolism, Stroke, Transient Ischemic Attack
- Trial name
- NCT05116280
- Where
- Greece
- Volunteers
- 200 people
- Sponsor
- University of Thessaly
End Stage Renal Disease
Improving Outcomes in Vascular Access
The IMPROVA study is designed to identify novel predictors of vascular access success or failure. Clinical assessment complimented by Doppler ultrasound is the only currently employed methods of assessing suitability for…
- Trial name
- IMPROVA (NCT02334696)
- Volunteers
- 32 people
- Sponsor
- University Hospital Birmingham
Subarachnoid Hemorrhage, Intracerebral Hemorrhage
Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?
The principal objective of this study is to compare the incidence of ventriculostomy related infections (VRIs) in patients who receive twenty-four hours of antibiotics, beginning no more than sixty minutes prior to EVD placement…
- Conditions
- Subarachnoid Hemorrhage, Intracerebral Hemorrhage, Ventriculitis, Cerebral, Hydrocephalus
- Trial name
- NCT05001750
- Testing
- Long term (continuous) prophylactic antibiotics, 24 hours antibiotics
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Montefiore Medical Center
Cardiovascular Diseases, Coronary Disease
Clinical Course of Coronary Artery Disease Among Blacks
To determine the clinical course of coronary artery disease among Blacks receiving medical care for symptomatic heart diseases.
- Conditions
- Cardiovascular Diseases, Coronary Disease, Myocardial Infarction, Heart Diseases
- Trial name
- NCT00005191
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Anterior ST-Segment Elevation Myocardial Infarction
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to…
- Trial name
- NCT07306182
- Testing
- SGC001 injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
ST-elevation Myocardial Infarction (STEMI), Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction
Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the…
- Trial name
- CHIP in STEMI (NCT07615023)
- Testing
- Clonal hematopoiesis assessment and cardiac magnetic resonance imaging
- Where
- Austria
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Peripheral Arterial Disease, Critical Limb Ischemia
Swedish Drug-elution Trial in Peripheral Arterial Disease
Peripheral arterial disease (PAD) causes reduced blood flow to the lower limb(s) due to stenosis or occlusion in the supplying arteries.
- Conditions
- Peripheral Arterial Disease, Critical Limb Ischemia, Intermittent Claudication
- Trial name
- SWEDEPAD (NCT02051088)
- Testing
- Revascularization with drug-eluting technology, Revascularization without drug-eluting technology, drug-coated balloons and/or drug-eluting stents
- Where
- Sweden
- Volunteers
- 3,556 people
- Sponsor
- Sahlgrenska University Hospital
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Diabetes, STEMI
Sweetheart-Register: Risk Management of Diabetics with Acute Myocardial Infarction
The Sweetheart register (Risk management of Diabetics with acute myocardial infarction) documents both the prevalence of pathologic glucose metabolism in consecutive high-risk patients with STEMI and NSTEMI in daily hospital…
- Conditions
- Diabetes, STEMI, NSTEMI, Myocardial Infarction
- Trial name
- Sweetheart (NCT01197742)
- Where
- 2 sites in Germany
- Volunteers
- 2,772 people
- Sponsor
- Stiftung Institut fuer Herzinfarktforschung
Cardioembolic Stroke, Atrial Fibrillation
Left Atrial Appendage Closure With SentreHeart Lariat® Device
The study cohort will consist of up to 50 patients who are candidates for Left Atrial Appendage (LAA) closure in whom oral anticoagulation is contraindicated.
- Trial name
- Lariat (NCT02681042)
- Testing
- Left atrial appendage closure, SentreHeart Lariat®
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Baylor Research Institute
Ischemic Heart Disease, Stable Angina
BioFreedom US IDE Feasibility Trial
The purpose of this study is to collect additional safety and effectiveness data for on the Biosensors BioFreedom™ BA9 Drug Coated Coronary Stent in patients with native, de novo coronary artery disease.
- Conditions
- Ischemic Heart Disease, Stable Angina, Unstable Angina, Silent Ischemia
- Trial name
- NCT02131142
- Testing
- BioFreedom drug coated coronary stent
- Where
- 13 sites in United States
- Volunteers
- 72 people
- Sponsor
- Biosensors Europe SA
Chronic Kidney Disease, Hypertension
Diuretics and Volume Overload in Early CKD
Almost 15% of Americans have chronic kidney disease (CKD), with an even higher rate in Veterans due to common risk factors such as high blood pressure and diabetes.
- Trial name
- DOCK (NCT05171686)
- Testing
- Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- VA Office of Research and Development
Peripheral Vascular Disease
Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.
This registry aims to collect detailed information about people in Canada who have Peripheral Artery Disease (PAD) and are receiving care in heart clinics while still able to walk and live in the community.
- Trial name
- PANACEA-O (NCT07500610)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Cardiology Research UBC
STEMI - ST Elevation Myocardial Infarction
Pretreatment With Unfractionated Heparin for ST Elevation Myocardial Infarction
Rupture of a coronary artery plaque leads to thrombotic occlusion of the coronary artery and would present as ST segment elevation myocardial infarction.
- Trial name
- UFH-STEMI (NCT05247424)
- Testing
- Unfractionated heparin
- Where
- Slovenia
- Volunteers
- 600 people
- Sponsor
- University Medical Centre Ljubljana
Ventricular Arrhythmia, Acute Myocardial Infarction (AMI)
Ventricular Arrhythmias in Acute Myocardial Infarction
Ventricular arrhythmias are a serious complication of myocardial infarction. The aim of this study is to provide reliable data on the management and mortality associated with ventricular arrhythmia in the setting of acute…
- Trial name
- ADVERSE-MI (NCT07517523)
- Where
- 8 sites in France
- Volunteers
- 500 people
- Sponsor
- Poitiers University Hospital
Aortic Aneurysm, Abdominal
TAP-Block in Abdominal Aortic Surgery
The primary outcome of this study was the evaluation of the efficacy of TAP block on pain intensity following open abdominal aortic surgery.
- Trial name
- TAP-CACAO (NCT03657979)
- Testing
- Ropivacaine
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Subdural Hematoma, Chronic
The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)
STEM Study is a pivotal, international, multi-center, prospective, randomized (1:1) controlled trial designed to provide an assessment of the safety and effectiveness of Middle Meningeal Artery (MMA) embolization with SQUID for…
- Trial name
- STEM (NCT04410146)
- Testing
- SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation
- Where
- 32 sites in United States, France and 2 more
- Volunteers
- 319 people
- Sponsor
- Balt USA
Hematologic Malignancies, Relapse
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by…
- Conditions
- Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
- Trial name
- NCT02145403
- Testing
- Carfilzomib, Tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.